Celgenerepeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe finds
Sep 30, 2020 - FiercePharma
Pharma has routinely defended its price hikesbyarguing thatresearch is risky and expensive,andrebatesto middlemenare growing.But a congressional probe unveiled Wednesday shows Celgene, now part of Bristol Myers Squibb, had another reason for hiking Revlimid's price: meeting its revenue goals.
Attacked for years over high drug prices, the pharmaceutical industry has routinely defended itselfbyarguing thatresearch is expensiveand risky and thatrebatesto middlemenare growing.
But a cong...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
